TWI728994B - 血漿ｄｎａ之單分子定序 - Google Patents
血漿ｄｎａ之單分子定序 Download PDFInfo
- Publication number
- TWI728994B TWI728994B TW105125873A TW105125873A TWI728994B TW I728994 B TWI728994 B TW I728994B TW 105125873 A TW105125873 A TW 105125873A TW 105125873 A TW105125873 A TW 105125873A TW I728994 B TWI728994 B TW I728994B
- Authority
- TW
- Taiwan
- Prior art keywords
- dna fragments
- plasma
- sequence
- dna
- serum
- Prior art date
Links
- 238000012163 sequencing technique Methods 0.000 title claims abstract description 118
- 108020004414 DNA Proteins 0.000 claims abstract description 437
- 239000012634 fragment Substances 0.000 claims abstract description 312
- 238000000034 method Methods 0.000 claims abstract description 151
- 108091028732 Concatemer Proteins 0.000 claims abstract description 71
- 210000002966 serum Anatomy 0.000 claims description 49
- 210000000349 chromosome Anatomy 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 32
- 230000002759 chromosomal effect Effects 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 abstract description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 4
- 210000002381 plasma Anatomy 0.000 description 142
- 210000003754 fetus Anatomy 0.000 description 36
- 238000007672 fourth generation sequencing Methods 0.000 description 35
- 125000006850 spacer group Chemical group 0.000 description 32
- 239000012472 biological sample Substances 0.000 description 31
- 238000009826 distribution Methods 0.000 description 31
- 239000000523 sample Substances 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 230000008774 maternal effect Effects 0.000 description 19
- 102000053602 DNA Human genes 0.000 description 18
- 238000005516 engineering process Methods 0.000 description 18
- 210000001766 X chromosome Anatomy 0.000 description 17
- 239000000306 component Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 238000010586 diagram Methods 0.000 description 14
- 239000012530 fluid Substances 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 12
- 230000011987 methylation Effects 0.000 description 12
- 238000007069 methylation reaction Methods 0.000 description 12
- 238000001712 DNA sequencing Methods 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 210000002593 Y chromosome Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000002159 abnormal effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000003960 Ligases Human genes 0.000 description 6
- 108090000364 Ligases Proteins 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 208000036878 aneuploidy Diseases 0.000 description 6
- 231100001075 aneuploidy Toxicity 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000005325 percolation Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 230000006607 hypermethylation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108020005031 Concatenated DNA Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011528 liquid biopsy Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003793 prenatal diagnosis Methods 0.000 description 2
- 238000009598 prenatal testing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010006223 Breast discharge Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- JZTPOMIFAFKKSK-UHFFFAOYSA-N O-phosphonohydroxylamine Chemical compound NOP(O)(O)=O JZTPOMIFAFKKSK-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 230000006800 cellular catabolic process Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 229940059082 douche Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
- G01N33/48721—Investigating individual macromolecules, e.g. by translocation through nanopores
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
- C12Q2521/501—Ligase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/151—Modifications characterised by repeat or repeated sequences, e.g. VNTR, microsatellite, concatemer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/191—Modifications characterised by incorporating an adaptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/197—Modifications characterised by incorporating a spacer/coupling moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/146—Concentration of target or template
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/60—Detection means characterised by use of a special device
- C12Q2565/631—Detection means characterised by use of a special device being a biochannel or pore
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nanotechnology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204396P | 2015-08-12 | 2015-08-12 | |
| US62/204,396 | 2015-08-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201718874A TW201718874A (zh) | 2017-06-01 |
| TWI728994B true TWI728994B (zh) | 2021-06-01 |
Family
ID=57983895
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105125873A TWI728994B (zh) | 2015-08-12 | 2016-08-12 | 血漿ｄｎａ之單分子定序 |
| TW110115619A TWI793586B (zh) | 2015-08-12 | 2016-08-12 | 血漿dna之單分子定序 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110115619A TWI793586B (zh) | 2015-08-12 | 2016-08-12 | 血漿dna之單分子定序 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11319586B2 (enExample) |
| EP (1) | EP3334843A4 (enExample) |
| JP (3) | JP6867045B2 (enExample) |
| CN (2) | CN115433769A (enExample) |
| AU (3) | AU2016305103C1 (enExample) |
| CA (1) | CA2995422A1 (enExample) |
| HK (1) | HK1248286A1 (enExample) |
| IL (3) | IL285795B (enExample) |
| MY (1) | MY188348A (enExample) |
| SA (1) | SA518390907B1 (enExample) |
| TW (2) | TWI728994B (enExample) |
| WO (1) | WO2017025059A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7084470B2 (ja) | 2017-08-23 | 2022-06-14 | エフ．ホフマン－ラ ロシュ アーゲー | 酵素のスクリーニング法 |
| KR20200060410A (ko) * | 2017-09-07 | 2020-05-29 | 쿠퍼제노믹스, 인크. | 비침습적 착상전 유전자 진단을 위한 방법과 시스템 (systems and methods for non-invasive preimplantation genetic diagnosis) |
| WO2019084158A1 (en) | 2017-10-26 | 2019-05-02 | Ultima Genomics, Inc. | METHODS AND SYSTEMS FOR SEQUENCE CALL |
| EP3731959B1 (en) | 2017-12-29 | 2025-10-08 | Clear Labs, Inc. | Automated priming and library loading device |
| WO2019204720A1 (en) * | 2018-04-20 | 2019-10-24 | The Regents Of The University Of California | Nucleic acid sequencing methods and computer-readable media for practicing same |
| WO2020185790A1 (en) | 2019-03-10 | 2020-09-17 | Ultima Genomics, Inc. | Methods and systems for sequence calling |
| CN114303202A (zh) | 2019-06-21 | 2022-04-08 | 酷博尔外科器械有限公司 | 用于确定胚胎中遗传模式的系统和方法 |
| WO2021108532A2 (en) * | 2019-11-25 | 2021-06-03 | William Marsh Rice University | Linear dna assembly for nanopore sequencing |
| US20230249178A1 (en) | 2020-07-08 | 2023-08-10 | Roche Sequencing Solutions, Inc. | Split-pool synthesis apparatus and methods of performing split-pool synthesis |
| WO2022081741A1 (en) | 2020-10-15 | 2022-04-21 | Roche Sequencing Solutions, Inc. | Electrophoretic devices and methods for next-generation sequencing library preparation |
| CN114507708A (zh) * | 2020-11-16 | 2022-05-17 | 唐纳德·李 | 一种制备长分子测序dna的方法 |
| WO2022194764A1 (en) | 2021-03-15 | 2022-09-22 | F. Hoffmann-La Roche Ag | Targeted next-generation sequencing via anchored primer extension |
| WO2022200485A1 (en) | 2021-03-26 | 2022-09-29 | F. Hoffmann-La Roche Ag | Hybridization buffer formulations |
| EP4314337A1 (en) | 2021-04-01 | 2024-02-07 | F. Hoffmann-La Roche AG | Immune cell counting of sars-cov-2 patients based on immune repertoire sequencing |
| IL307398A (en) * | 2021-04-12 | 2023-12-01 | Univ Hong Kong Chinese | Base change analysis using electrical signals |
| WO2023023561A1 (en) * | 2021-08-17 | 2023-02-23 | Quantapore, Inc. | Multiplex binding assays with optical nanopore readout |
| US20250243536A1 (en) * | 2021-10-18 | 2025-07-31 | Belgian Volition Srl | Use of nanopore sequencing for determining the origin of circulating dna |
| EP4547839A1 (en) | 2022-06-30 | 2025-05-07 | Kapa Biosystems, Inc. | Controlling for tagmentation sequencing library insert size using archaeal histone-like proteins |
| CN114898802B (zh) * | 2022-07-14 | 2022-09-30 | 臻和(北京)生物科技有限公司 | 基于血浆游离dna甲基化测序数据的末端序列频率分布特征确定方法、评价方法及装置 |
| WO2024046992A1 (en) | 2022-09-02 | 2024-03-07 | F. Hoffmann-La Roche Ag | Improvements to next-generation target enrichment performance |
| JP2026519344A (ja) | 2023-04-13 | 2026-06-16 | ベンタナ メディカル システムズ， インコーポレイテッド | 固定固形腫瘍に対する増殖アッセイ |
| JP2026524816A (ja) | 2023-06-14 | 2026-07-24 | エフ． ホフマン－ラ ロシュ アーゲー | 加速された５－ホルミルシトシンのマーキングおよび核酸メチル化シーケンシングにおける使用 |
| WO2025193604A1 (en) | 2024-03-11 | 2025-09-18 | Ventana Medical Systems, Inc. | Non-enzymatic dissociation of ffpe tissue and generation of single cells with intact cell surface markers |
| WO2025210056A1 (en) | 2024-04-03 | 2025-10-09 | Roche Sequencing Solutions, Inc. | In vitro amplification of dna methylation patterns |
| WO2025247632A1 (en) | 2024-05-27 | 2025-12-04 | European Molecular Biology Laboratory | Preparation of cell-free fragmented nucleic acids for genetic analysis sequencing |
| WO2026082489A1 (en) | 2024-10-18 | 2026-04-23 | F. Hoffmann-La Roche Ag | Universal pcr to boost molecule recovery in cell free dna library preparation and target enrichment workflows |
| WO2026087220A1 (en) | 2024-10-22 | 2026-04-30 | F. Hoffmann-La Roche Ag | Preparation of dna libraries for next generation sequencing using y-adapters modified with phosphorothioate bonds |
| WO2026093331A1 (en) | 2024-10-28 | 2026-05-07 | F. Hoffmann-La Roche Ag | Hairpin adapter constructs and primers to generate next-generation sequencing library molecules |
| WO2026099278A1 (en) | 2024-11-08 | 2026-05-15 | F. Hoffmann-La Roche Ag | Normalizing and pooling of pcr-free sequencing libraries |
| WO2026151663A1 (en) | 2025-01-07 | 2026-07-16 | Kapa Biosystems, Inc. | Selective rna tagging methods of total nucleic samples for sequencing applications |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006095169A1 (en) * | 2005-03-08 | 2006-09-14 | Lingvitae As | Method for preparing polynucleotides for analysis |
| US20120045771A1 (en) * | 2008-12-11 | 2012-02-23 | Febit Holding Gmbh | Method for analysis of nucleic acid populations |
| WO2012060595A2 (en) * | 2010-11-01 | 2012-05-10 | Lg Electronics Inc. | Structure with nanopore and apparatus for determining sequences of nucleic acids including the same |
| US20130040827A1 (en) * | 2011-08-14 | 2013-02-14 | Stephen C. Macevicz | Method and compositions for detecting and sequencing nucleic acids |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020197618A1 (en) | 2001-01-20 | 2002-12-26 | Sampson Jeffrey R. | Synthesis and amplification of unstructured nucleic acids for rapid sequencing |
| JP2008161056A (ja) | 2005-04-08 | 2008-07-17 | Hiroaki Mita | Ｄｎａ配列解析装置、ｄｎａ配列解析方法およびプログラム |
| US12054776B2 (en) | 2007-07-23 | 2024-08-06 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing |
| AU2009325069B2 (en) | 2008-12-11 | 2015-03-19 | Pacific Biosciences Of California, Inc. | Classification of nucleic acid templates |
| LT3241914T (lt) | 2009-11-05 | 2019-04-25 | The Chinese University Of Hong Kong | Vaisiaus genomo analizė iš motinos biologinio mėginio |
| CA2780016C (en) | 2009-11-06 | 2017-09-19 | The Chinese University Of Hong Kong | Size-based genomic analysis |
| US9121823B2 (en) * | 2010-02-19 | 2015-09-01 | The Trustees Of The University Of Pennsylvania | High-resolution analysis devices and related methods |
| KR102040307B1 (ko) | 2010-11-30 | 2019-11-27 | 더 차이니즈 유니버시티 오브 홍콩 | 암과 연관된 유전적 또는 분자적 이상들의 검출 |
| KR20140050067A (ko) * | 2011-07-25 | 2014-04-28 | 옥스포드 나노포어 테크놀로지즈 리미티드 | 막횡단 포어를 사용한 이중 가닥 폴리뉴클레오티드 서열분석을 위한 헤어핀 루프 방법 |
| GB2485635B (en) * | 2011-07-26 | 2012-11-28 | Verinata Health Inc | Method for determining the presence or absence of different aneuploidies in a sample |
| CA2861457A1 (en) | 2012-01-20 | 2013-07-25 | Genia Technologies, Inc. | Nanopore based molecular detection and sequencing |
| GB2559073A (en) * | 2012-06-08 | 2018-07-25 | Pacific Biosciences California Inc | Modified base detection with nanopore sequencing |
| JP2015525077A (ja) * | 2012-06-15 | 2015-09-03 | ジェニア・テクノロジーズ・インコーポレイテッド | チップの構成および高精度な核酸配列決定 |
| US11261494B2 (en) * | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| GB201215449D0 (en) | 2012-08-30 | 2012-10-17 | Zoragen Biotechnologies Llp | Method of detecting chromosonal abnormalities |
| HUE053822T2 (hu) | 2012-09-20 | 2021-07-28 | Univ Hong Kong Chinese | Nem invazív módszer daganat metilom meghatározása plazmából |
| IL274464B2 (en) * | 2013-12-11 | 2023-08-01 | Accuragen Holdings Ltd | Preparations and methods for the detection of rare sequence variants |
| WO2016077313A1 (en) * | 2014-11-11 | 2016-05-19 | Bgi Shenzhen | Multi-pass sequencing |
| AU2016406443A1 (en) | 2016-05-10 | 2018-11-15 | Nec Corporation | Demand and supply adjustment system, control apparatus, control method, and program |
-
2016
- 2016-08-12 US US15/235,630 patent/US11319586B2/en active Active
- 2016-08-12 TW TW105125873A patent/TWI728994B/zh active
- 2016-08-12 CA CA2995422A patent/CA2995422A1/en active Pending
- 2016-08-12 WO PCT/CN2016/094802 patent/WO2017025059A1/en not_active Ceased
- 2016-08-12 MY MYPI2018000139A patent/MY188348A/en unknown
- 2016-08-12 CN CN202211147693.8A patent/CN115433769A/zh active Pending
- 2016-08-12 TW TW110115619A patent/TWI793586B/zh active
- 2016-08-12 EP EP16834683.1A patent/EP3334843A4/en active Pending
- 2016-08-12 IL IL285795A patent/IL285795B/en unknown
- 2016-08-12 HK HK18108082.2A patent/HK1248286A1/zh unknown
- 2016-08-12 AU AU2016305103A patent/AU2016305103C1/en active Active
- 2016-08-12 JP JP2018506601A patent/JP6867045B2/ja active Active
- 2016-08-12 CN CN201680046621.0A patent/CN107849607B/zh active Active
-
2018
- 2018-01-22 IL IL257074A patent/IL257074B/en unknown
- 2018-02-12 SA SA518390907A patent/SA518390907B1/ar unknown
-
2020
- 2020-03-26 AU AU2020202153A patent/AU2020202153B2/en active Active
-
2021
- 2021-03-31 JP JP2021060027A patent/JP7506408B2/ja active Active
-
2022
- 2022-03-18 US US17/698,574 patent/US20220205038A1/en active Pending
- 2022-06-22 IL IL294192A patent/IL294192B2/en unknown
-
2023
- 2023-04-27 AU AU2023202572A patent/AU2023202572B2/en active Active
-
2024
- 2024-06-07 JP JP2024092950A patent/JP7810455B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006095169A1 (en) * | 2005-03-08 | 2006-09-14 | Lingvitae As | Method for preparing polynucleotides for analysis |
| US20120045771A1 (en) * | 2008-12-11 | 2012-02-23 | Febit Holding Gmbh | Method for analysis of nucleic acid populations |
| WO2012060595A2 (en) * | 2010-11-01 | 2012-05-10 | Lg Electronics Inc. | Structure with nanopore and apparatus for determining sequences of nucleic acids including the same |
| US20130040827A1 (en) * | 2011-08-14 | 2013-02-14 | Stephen C. Macevicz | Method and compositions for detecting and sequencing nucleic acids |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7810455B2 (ja) | 血漿ｄｎａの単分子配列決定 | |
| TWI867325B (zh) | 利用血漿中dna的尺寸及數量畸變以偵測癌症 | |
| JP6161607B2 (ja) | サンプルにおける異なる異数性の有無を決定する方法 | |
| ES2659487T3 (es) | Análisis basado en el tamaño de la fracción de ADN fetal en el plasma materno | |
| TWI807306B (zh) | 血漿粒線體dna分析之應用 | |
| CN108026572A (zh) | 游离dna的片段化模式的分析 | |
| CN110023509A (zh) | 基因型分型测定中的非独特条形码 | |
| HK40083172A (en) | Single-molecule sequencing of plasma dna | |
| HK1245850B (en) | Single-molecule sequencing of plasma dna | |
| HK1246361B (en) | Size-based analysis of fetal dna fraction in maternal plasma | |
| HK1245842B (en) | Size-based analysis of fetal dna fraction in maternal plasma | |
| HK1237825A1 (en) | Applications of plasma mitochondrial dna analysis | |
| HK1240279B (en) | Using size and number aberrations in plasma dna for detecting cancer | |
| HK1205204B (en) | Rapid aneuploidy detection |